Ryan Specialty's fifteen year run of double digit organic growth ended in 2026. Full year guidance moved twice this year, from high single digits in February down to mid single digits by April, and the 35% margin target management set for 2027 has been quietly deferred with no new date attached. The board's answer has been to raise the buyback authorization to $600 million and step back from the acquisitive model that built the platform in the first place, with management saying in July that no meaningful deal is likely before 2027.

One thing worth flagging: The headline retention numbers look fine, producer retention held at 96% or better every year from 2020 through 2025, but the number underneath it tells a different story. The share of producers actually growing their book of business fell from 78% in 2024 to 71% in 2025, a seven point drop buried in the 10-K rather than the investor presentation. Ryan is keeping its people. What's less clear is whether it's keeping their output, right as a large, unseasoned 2025 hiring class waits until 2027 to turn margin accretive.

Sources and Methods

Each Dossier is built from primary documents: SEC filings and statutory financials, earnings call and investor day transcripts, management presentations, rating agency and regulatory records, company press releases, and trade press. We also work the channels where operating problems surface before they reach an earnings call, including expert interviews with market participants, agent and broker forums, and practitioner communities. Equity analyst commentary is used to map where the sell-side disagrees and is treated as opinion rather than evidence.

The Intelligence Council is editorially independent. No company reviews a Dossier before publication.